Inova is First in the Mid-Atlantic to Offer New Bypass Alternative

FALLS CHURCH, VA (May 1, 2014) – Inova Heart and Vascular Institute is the first facility in the Washington, DC metro area and the mid-Atlantic United States to adopt the Diamondback 360® Coronary Orbital Atherectomy System (OAS).

This technology is the first evidence-based, safe treatment approved by FDA for severely calcified coronary lesions. The Diamondback 360® Coronary OAS uses a patented combination of differential sanding and centrifugal force to reduce arterial calcium that can cause complications when treating Coronary Artery Disease (CAD), a life-threatening condition.

Arterial calcium is a common occurrence and can lead to significant complications, with moderate to severe arterial calcium present in nearly 40 percent of patients undergoing a percutaneous coronary intervention in the U.S.

This tool gives physicians the ability to treat a challenging patient population that has often only had the option of surgery due to their state of coronary artery disease. We hope to now be able to provide less invasive procedures with safe and effective results,” says Dr. Shawn Yazdani, MD, FACC, FSCAI of Carient Heart and Vascular.

Mary Obannon had one of the first Diamondback 360® procedures in Northern Virginia on April 30, 2014. Because of her age and condition, she did not have an option for open-heart surgery. She was released the next day.

The Diamondback 360® Coronary OAS uses a diamond-coated crown that sands away calcium in severely calcified coronary arteries, enabling stent deployment. Without reducing the calcium, the stent cannot be placed safely.

At one year, the results from the ORBIT II clinical study showed that using the Diamondback 360® Coronary OAS technology exceeded the trial’s primary safety and effectiveness endpoints within one of the most challenging patient populations.

“Inova Heart and Vascular Institute is pleased to offer our patients undergoing percutaneous coronary intervention procedures with the first evidence-based option approved by the FDA. It may reduce the need for coronary bypass surgery in some patients.” said Dr. Bryan Raybuck, Inova Heart and Vascular Institute Cardiac Cauterization Lab Medical Director.

About Coronary Arterial Disease

Coronary Artery Disease (CAD) is a life-threatening condition and leading cause of death in men and women in the United States. CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow. The risk of CAD increases if a person has one or more of the following: high blood pressure, abnormal cholesterol levels, diabetes, or family history of early heart disease. According to the American Heart Association, 16.3 million people in the United States have been diagnosed with CAD. CAD is the most common form of heart disease and claims more than 600,000 lives, or 1 in 4 Americans, in the United States each year. According to estimates, significant arterial calcium is present in nearly 40 percent of patients undergoing a percutaneous coronary intervention (PCI). Significant calcium contributes to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used, including a significantly higher occurrence of death and MACE.

About Inova
Inova is a not-for-profit health care system located in the Washington, D.C. metropolitan area, serving over two million people with over 1,700 licensed beds based in Northern Virginia. Inova consists of five hospitals including the area’s only Level 1 Trauma Center and Level 4 Neonatal Intensive Care unit. Inova encompasses many health services including the nationally and internationally recognized Inova Heart and Vascular Institute (IHVI), Inova Translational Medicine Institute (ITMI) on genomics, Inova Neuroscience Institute and Inova Children’s Hospital. Inova’s mission is to improve the health of the diverse community it serves through excellence in patient care, education and research. More information and statistics about Inova is at